HealthEquity price target raised to $97 from $93 at BofA

BofA analyst Allen Lutz raised the firm’s price target on HealthEquity to $97 from $93 and keeps a Buy rating on the shares. HealthEquity reported a “strong quarter” and gave FY25 revenue and EBITDA guidance that was in line with the Street, notes the analyst, who says there were “no surprises” in the Q4 print and FY25 outlook. Following the report, the firm raised its target multiple to account for greater line of sight into earnings growth, the analyst tells investors.